

Jen R.,  
Stem Cell and Double Lung  
Transplant Recipient



# Revolutionizing Chimerism Monitoring

**THE LATEST INNOVATION IN CHIMERISM TESTING OFFERS  
STREAMLINED WORKFLOW WITH BEST-IN-CLASS SENSITIVITY**

Chimerism changes after hematopoietic cell transplant  
can be an early indication of relapse\*


Early detection can lead to early intervention

# What is AlloSeq HCT?

- A **NGS based chimerism testing solution** that is able to determine the relative contribution of up to 3 genomes in a single sample i.e. up to two donors per recipient
- A **kit based test** that offers high quality data with a recommended input of **10 ng of gDNA** and up to **24 samples per batch**
- A one-step multiplex assay that utilizes **202 SNPs** across all autosomal chromosomes to differentiate between recipient and donor(s) gDNA
- A **highly sensitive, scalable assay** with time-saving automated analysis software

AlloSeq HCT is a simple and fast assay with **minimal hands-on time.**

**gDNA Sample to Report in Less than 24 hours**




\*References for early rejection

- Rashef et al BBMT 2014;20:1758-66
- Tang et al BBMT 2014;20:1139:1144

# AlloSeq HCT offers **accurate** and **precise** results

**72 DNA mixtures simulating post-transplant samples demonstrate test dynamic range of 0.1% - 99.9%**



AlloSeq HCT accuracy was measured against expected using artificially mixed gDNA samples extracted from fresh whole blood. 72 data points were generated achieving signal linearity with a correlation and slope close to 1. The Limit of Quantification (LOQ) obtained is shown and marked on the graph (for post transplant samples with a single donor)

## AlloSeq HCT is reproducible with **high quality data**

**Internal and external validation produces reproducible and precise data**

**TABLE 1: Internal Validation at CareDx**

Expected Fraction	0.4%	1%	10%	50%	85%	98%
Observed Fraction	0.5%	1.1%	10.5%	50.7%	85.2%	98%
Coefficient of Variation	8.6%	7.7%	2.1%	0.2%	0.5%	0.1%
Sample Number (N)	20	12	11	3	3	4

**TABLE 2: External Validation**

Expected Fraction	5%	50%	95%
Observed Fraction	4.8%	48.2%	94.7%
Coefficient of Variation	4.8%	0.5%	0.2%
Sample Number (N)	3	3	3

Table 1 & 2 represent the AlloSeq HCT average result for artificially mixed samples across a number of technical replicates. Table 2 shows validation results at an external lab confirming the reproducibility obtained at CareDx.

# AlloSeq HCT provides easy and fast results with automated analysis.

The Windows based software is user-friendly and LIMS compatible.

All samples are reported on a single screen

## Post-transplant samples

SAMPLE NAME	ANALYSIS DATE	DNA TYPE	SAMPLE QUALITY	RECIPIENT DNA	DONOR-1 DNA	DONOR-2 DNA	DETAILS VIEW
E10R1	NA	gDNA	Pass	0.83%	8.89%	90.27%	
E10R10	NA	gDNA	Pass	1.01%	8.58%	90.41%	
E10R11	NA	gDNA	Pass	0.89%	8.85%	90.26%	

## Recipient-only

SAMPLE NAME	ANALYSIS DATE	DNA TYPE	SAMPLE QUALITY	DETAILS VIEW
Blood3R5	2019-11-21	gDNA	Pass	

## Donor-only

SAMPLE NAME	ANALYSIS DATE	DNA TYPE	SAMPLE QUALITY	DETAILS VIEW
Blood1R6	2019-11-21	gDNA	Pass	
Blood2R4	2019-11-21	gDNA	Pass	

“Detailed report by sample can be seen by clicking on “Details view”

**Detailed % DNA display for each sample**

PRODUCT	PRODUCT NUMBER	DESCRIPTION
AlloSeq® HCT	ASHCT.1(24)	Includes all the reagents required to make 24 NGS libraries

For Research Use Only. Not for use in diagnostic procedures.

Visit [www.caredxinc.com/alloseq-hct](http://www.caredxinc.com/alloseq-hct) for more information  
For inquiries, contact your CareDx representative or reach out to us:

### Phone numbers:

Americas – [orders-US@caredx.com](mailto:orders-US@caredx.com)  
EMEA – [orders-at@caredx.com](mailto:orders-at@caredx.com)  
Nordics – [orders-aus@caredx.com](mailto:orders-aus@caredx.com)  
APAC – [orders-se@caredx.com](mailto:orders-se@caredx.com)

